These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 17391147

  • 1. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 2. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 3. Insulin detemir: a new basal insulin analogue.
    Soran H, Younis N.
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [Abstract] [Full Text] [Related]

  • 4. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 5. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 6. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 7. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 8. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 9. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH, Nattrass M, Pieber TR.
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [Abstract] [Full Text] [Related]

  • 10. Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
    Russell-Jones D, Khan R.
    Diabetes Obes Metab; 2007 Nov; 9(6):799-812. PubMed ID: 17924864
    [Abstract] [Full Text] [Related]

  • 11. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 13. [Insulin analogues: place of detemir (Levemir)].
    Dorchy H, Sternon J.
    J Pharm Belg; 2006 Aug; 61(2):58-62. PubMed ID: 16866083
    [Abstract] [Full Text] [Related]

  • 14. Insulin detemir--a new basal insulin analog.
    Goldman-Levine JD, Lee KW.
    Ann Pharmacother; 2005 Mar; 39(3):502-7. PubMed ID: 15657117
    [Abstract] [Full Text] [Related]

  • 15. [Insulin analogues: place of detemir (levemir)].
    Dorchy H, Sternon J.
    Rev Med Brux; 2006 Mar; 27(2):89-94. PubMed ID: 16736846
    [Abstract] [Full Text] [Related]

  • 16. At last, a weight neutral insulin?
    Fritsche A, Häring H.
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S41-6. PubMed ID: 15306837
    [Abstract] [Full Text] [Related]

  • 17. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ.
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [Abstract] [Full Text] [Related]

  • 18. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 19. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN.
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [Abstract] [Full Text] [Related]

  • 20. Use of insulin and weight gain: optimizing diabetes nutrition therapy.
    Daly A.
    J Am Diet Assoc; 2007 Aug; 107(8):1386-93. PubMed ID: 17659906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.